Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $236.47, for a total transaction of $851,292.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,741.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

United Therapeutics Trading Up 1.1 %

Shares of NASDAQ:UTHR opened at $237.00 on Thursday. United Therapeutics Co. has a 12 month low of $204.44 and a 12 month high of $261.54. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $232.93 and its 200 day simple moving average is $228.74. The firm has a market cap of $11.15 billion, a price-to-earnings ratio of 11.95 and a beta of 0.52.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts’ consensus estimates of $4.28 by $0.08. The business had revenue of $614.70 million during the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The firm’s revenue for the quarter was up 25.1% compared to the same quarter last year. During the same quarter last year, the firm earned $2.67 earnings per share. As a group, research analysts forecast that United Therapeutics Co. will post 23.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in UTHR. Norges Bank bought a new position in United Therapeutics in the fourth quarter valued at $100,519,000. Avidity Partners Management LP bought a new position in United Therapeutics in the fourth quarter valued at $52,158,000. Comerica Bank grew its position in United Therapeutics by 2,697.2% in the third quarter. Comerica Bank now owns 156,587 shares of the biotechnology company’s stock valued at $35,368,000 after purchasing an additional 150,989 shares in the last quarter. Victory Capital Management Inc. grew its position in United Therapeutics by 309.7% in the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock valued at $29,501,000 after purchasing an additional 101,419 shares in the last quarter. Finally, TD Asset Management Inc grew its position in shares of United Therapeutics by 1,066.4% in the 4th quarter. TD Asset Management Inc now owns 82,951 shares of the biotechnology company’s stock valued at $18,240,000 after acquiring an additional 75,839 shares during the period. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a report on Monday, February 5th. Wells Fargo & Company increased their target price on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a report on Thursday, March 7th. The Goldman Sachs Group upgraded shares of United Therapeutics from a “sell” rating to a “neutral” rating and increased their target price for the stock from $213.00 to $215.00 in a report on Monday, February 12th. Wedbush restated an “outperform” rating and set a $308.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, HC Wainwright restated a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $294.25.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.